Analysis of scientific evidence on the effectiveness of immunomodulation in cancer: a systematic review

Authors

DOI:

https://doi.org/10.33448/rsd-v11i9.22721

Keywords:

Immunomodulation; Efficacy; Cancer.

Abstract

Objective: To analyze the scientific evidence from studies on the effectiveness of immunomodulation in cancer. Methodology: This is a systematic review that searched for studies in the respective databases such as Pubmed, Scopus, Cinahl, Web of Science, and The Cochrane Data Base, using descriptors in English, selected in the Medical Subject Headings- MeSH. Soon after cataloging, the studies were analyzed through the Consolidated Standards of Reporting Trials-CONSORT, and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE), the study sample consisted of nine articles. Results: Analysis of the studies reveals that immunomodulators have an average efficacy rate of 56% for some neoplasms. It was also observed that some substances showed good efficacy in the immunomodulation axis, such as Vitamin D, which decreases the relative risk for colon, breast, and prostate cancer. Immunomodulation was successful in increasing the survival of patients with endocrine (52%) and dermatological (45%) cancers who had low-grade (57%) immunity-related adverse events (irAE). Conclusion: Immunomodulatory therapy is evidenced as an advance in cancer therapy for presenting promising results, showing effectiveness for certain neoplasms.

Author Biographies

Vinicius Lino de Souza Neto, University Ninth of July

Enfermeiro. Doutorando pela Universidade Federal de São Paulo. Professor do curso de graduação de Enfermagem da Universidade Nove de Julho/ Ciencias da saúde.

Giovanna Pereira Holanda , University Ninth of July

Academic of the Medicine course of the Nove de Julho University

Joane Caroline Menck, University Ninth of July

Academic of the Medicine course of the Nove de Julho University

Breno Amin De Lima Silveira , University Ninth of July

Academic of the Medicine course of the Nove de Julho University

Daniela Parra Serafim, University Ninth of July

Academic of the Medicine course of the Nove de Julho University

Victoria Carolini Mendes, University Ninth of July

Academic of the Medicine course of the Nove de Julho University

Eduarda Cardoso Franco , University Ninth of July

Academic of the Medicine course of the Nove de Julho University

Hugo Justino Branda , University Ninth of July

Academic of the Medicine course of the Nove de Julho University

Andrezza Alves Vasconcelos Teixeira, University Ninth of July

Academic of the Medicine course of the Nove de Julho University

Pedro Henrique de Freitas Cassoli , University Ninth of July

Academic of the Medicine course of the Nove de Julho University

Bárbara Lima Guerra, University Ninth of July

Academic of the Medicine course of the Nove de Julho University

References

Ascierto, P. A., Brugarolas, J., Buonaguro, L., Butterfield, L. H., Carbone, D., Daniele, B., Ferris, R., Fox, B. A., Galon, J., Gridelli, C., Kaufman, H. L., Klebanoff, C. A., Melero, I., Nathan, P., Paulos, C. M., Ruella, M., Sullivan, R., Zarour, H., & Puzanov, I. (2018). Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (2017). Journal for immunotherapy of cancer, 6(1), 69.

Chen, G. et al (2018). Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature 560, 382–386.

Davda, J., Declerck, P., Hu-Lieskovan, S., Hickling, T. P., Jacobs, I. A., Chou, J., Salek-Ardakani, S., &Kraynov, E. (2019). Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics. Journal for immunotherapy of cancer, 7(1), 105.

De Mattos-Arruda, L., Blanco-Heredia, J., Aguilar-Gurrieri, C., Carrillo, J., & Blanco, J. (2020). New emerging targets in cancer immunotherapy: the role of neoantigens. ESMO open, 4(Suppl 3), e000684.

Di Trolio, R., Simeone, E., Di Lorenzo, G., Buonerba, C., & Ascierto, P. A. (2015). The use of interferon in melanoma patients: a systematic review. Cytokine & growth factor reviews, 26(2), 203–212.

Dunn, J., & Rao, S. (2017). Epigenetics and immunotherapy: The current state of play. Molecular immunology, 87, 227–239.

Esfahani, K., Roudaia, L., Buhlaiga, N., Del Rincon, S. V., Papneja, N., & Miller, W. H., Jr (2020). A review of cancer immunotherapy: from the past, to the present, to the future. Current oncology (Toronto, Ont.), 27(Suppl 2), S87–S97.

Fujimoto, D., Yoshioka, H., Kataoka, Y., Morimoto, T., Kim, Y. H., Tomii, K., Ishida, T., Hirabayashi, M., Hara, S., Ishitoko, M., Fukuda, Y., Hwang, M. H., Sakai, N., Fukui, M., Nakaji, H., Morita, M., Mio, T., Yasuda, T., Sugita, T., & Hirai, T. (2018). Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: A multicenter retrospective cohort study. Lung cancer (Amsterdam, Netherlands), 119, 14–20.

Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Rutkowski, P., Cowey, C. L., Lao, C. D., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Hill, A., Hogg, D., Marquez-Rodas, I., Jiang, J., Rizzo, J., Larkin, J., &Wolchok, J. D. (2018). Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. The Lancet. Oncology, 19(11), 1480–1492.

Kottschade L. A. (2019). The Future of Immunotherapy in the Treatment of Cancer. Seminars in oncology nursing, 35(5), 150934.

Lee, S., & Margolin, K. (2011). Cytokines in cancer immunotherapy. Cancers, 3(4), 3856–3893.

Lin, H. et al. (2018). Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. J. Clin. Invest. 128, 805–815.

O'Donnell, J. S., Teng, M., & Smyth, M. J. (2019). Cancer immunoediting and resistance to T cell-based immunotherapy. Naturereviews. Clinicaloncology, 16(3), 151–167.

Reyes, S. J., González, K. B., Rodríguez, C., Navarrete-Muñoz, C., Salazar, A. P., Villagra, A., Caglevic, C., & Hepp, M. I. (2020). Imunoterapia do câncer: uma atualização. Revista médica de Chile, 148 (7), 970-982.

Rota, G. et al (2018). Shp-2 is dispensable for establishing T cell exhaustion and for PD-1 signaling in vivo. Cell Rep. 23, 39–49.

Scharovsky, O. Graciela, Matar, Pablo, Rozados, Viviana R., Rico, María J., ZacaríasFluck, Mariano F., Mainetti, Leandro E., Fernández Zenobi, M. Virginia, Roggero, Eduardo A., Gervasoni, Silvia I., Rossa, Ana, Perroud, Herman A., Sánchez, Andrea M., Celoria, Guillermo C., & Font, María T. (2012). Inmunomodulación y antiangiogénesis en la terapéutica oncológica: De la investigación básica a la clínica. Medicina, 72(1), 47-57.

Sugiura, D. et al (2019). Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses. Science 364, 558–566.

Teixeira, H., Dias. L., Menão. T., Oliveira. E. (2019). Immune checkpoint proteins as new target for cancer immunotherapy: literature review. HU rev. 45(3):325-333.

Wang, D. Y., Salem, J. E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., Rathmell, W. K., Ancell, K. K., Balko, J. M., Bowman, C., Davis, E. J., Chism, D. D., Horn, L., Long, G. V., Carlino, M. S., Lebrun-Vignes, B., & Johnson, D. B. (2018). Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA oncology, 4(12), 1721–1728.

Zhou, X., Yao, Z., Yang, H., Liang, N., Zhang, X., & Zhang, F. (2020). Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC medicine, 18(1), 87.

Downloads

Published

16/07/2022

How to Cite

SOUZA NETO, V. L. de .; HOLANDA , G. P. .; MENCK, J. C. .; SILVEIRA , B. A. D. L. .; SERAFIM, D. P. .; MENDES, V. C. .; FRANCO , E. C. .; BRANDA , H. J. .; TEIXEIRA, A. A. V. .; CASSOLI , P. H. de F. .; GUERRA, . B. L. .; COSTA FILHO, M. T. M. da . Analysis of scientific evidence on the effectiveness of immunomodulation in cancer: a systematic review . Research, Society and Development, [S. l.], v. 11, n. 9, p. e47311922721, 2022. DOI: 10.33448/rsd-v11i9.22721. Disponível em: https://rsdjournal.org/index.php/rsd/article/view/22721. Acesso em: 30 sep. 2022.

Issue

Section

Health Sciences